Vilazodone - Revision history

MDElliottMD: Tier 2 taxonomy consolidation: remove Category:Serotonin Reuptake Inhibitors

2026-05-21T18:28:28Z

Tier 2 taxonomy consolidation: remove Category:Serotonin Reuptake Inhibitors

← Older revision		Revision as of 18:28, 21 May 2026
Line 26:		Line 26:
	[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]		[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]
	[[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]]		[[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]]
	~~[[Category:Serotonin Reuptake Inhibitors]]~~

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:12Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 14:		Line 14:
	\| pregnancy = Limited data; weigh benefits/risks		\| pregnancy = Limited data; weigh benefits/risks
	\| legal = Rx		\| legal = Rx
	\| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.		\| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism, similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.

	In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).		In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).

Maintenance script: Terminology sweep: drug/medication → medicine

2026-05-16T02:27:27Z

Terminology sweep: drug/medication → medicine

← Older revision		Revision as of 02:27, 16 May 2026
Line 16:		Line 16:
	\| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.		\| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.

	In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The ~~drug~~ carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).		In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).
	\| pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity.		\| pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity.
	\| effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients.		\| effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients.

Maintenance script: Expand Vilazodone with Stahl-sourced detail (with skepticism)

2026-05-16T02:03:47Z

Expand Vilazodone with Stahl-sourced detail (with skepticism)

← Older revision		Revision as of 02:03, 16 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	~~\| generic = Vilazodone~~		\| brand = Viibryd
	\| brand = Viibryd		\| classes = Serotonin partial agonist reuptake inhibitor (SPARI)
	~~\| structure =~~		\| mechanism = Combines SERT inhibition (typical SSRI mechanism) with 5HT1A receptor partial agonism. The 5HT1A partial agonism is proposed to: (1) provide intrinsic 5HT1A agonist activity beyond what SERT inhibition produces, and (2) accelerate downregulation of 5HT1A autoreceptors, potentially shortening the typical 4-6 week onset for SSRI effect.
	\| classes = ~~SSRI, Antidepressant~~		\| uses = Major depressive disorder in adults (FDA-approved 2011)
	\| mechanism = SSRI and 5-~~HT1A partial agonist~~		\| starting_dose = 10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food)
	\| uses =		\| preparations = 10 mg, 20 mg, 40 mg tablets
	\| starting_dose =		\| fda_max = 40 mg/d
	\| preparations =		\| routes = Oral
	\| fda_max =		\| onset = 4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism)
	\| routes =		\| duration = Daily dosing
	\| onset =		\| halflife = ~25 hours
	\| duration =		\| bioavailability = ~72% (with food); much lower fasting (~36%)
	\| halflife =		\| pregnancy = Limited data; weigh benefits/risks
	\| bioavailability =		\| legal = Rx
	\| pregnancy =		\| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.
	\| legal =
	\| intro =		In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The drug carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).
	~~\| pharmacokinetics =~~		\| pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity.
	\| pharmacodynamics =		\| effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients.
	~~\| indications =~~		\| interactions = <pharmaInteractions/>
	~~\| dosing~~ =
	\| effects =
	\| interactions = <pharmaInteractions/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}

Line 34:		Line 25:
	[[Category:Multimodal Serotonergic Agents]]		[[Category:Multimodal Serotonergic Agents]]
	[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]		[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]
			[[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]]
			[[Category:Serotonin Reuptake Inhibitors]]

MDElliottMD: Comprehensive categorization: +Multimodal Serotonergic Agents, Selective Serotonin Reuptake Inhibitors (SSRIs)

2026-05-15T18:42:08Z

Comprehensive categorization: +Multimodal Serotonergic Agents, Selective Serotonin Reuptake Inhibitors (SSRIs)

← Older revision		Revision as of 18:42, 15 May 2026
Line 32:		Line 32:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]
			[[Category:Multimodal Serotonergic Agents]]
			[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:13Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:53Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:38Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Vilazodone
+| generic            = Vilazodone
-| brand             = Viibryd
+| brand              = Viibryd
-| classes           = SSRI, Antidepressant
+| structure          =
-| mechanism         = SSRI and 5-HT1A partial agonist
+| classes            = SSRI, Antidepressant
 }}
 [[Category:Antidepressants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Vilazodone
| brand = Viibryd
| classes = SSRI, Antidepressant
| mechanism = SSRI and 5-HT1A partial agonist
}}
[[Category:Antidepressants]]